Search
Close this search box.

Cystic Fibrosis

VX20-445-126

STUDY OUTLINE

The study aims to evaluate the effects of elexacaftor/tezacaftor/ivacaftor on cough and physical activity using wearable technology.

To find out if this trial is suitable for you please register below or contact our Clinical Trials Team at admin@resphealth.uwa.edu.au or phone 6151 0888.

ELIGIBILITY & REQUIREMENTS

  • Aged 18 or over with a diagnosis of cystic fibrosis and the F508del/MF mutation.

WHAT'S INVOLVED

  • Forced expiratory volume in 1 second (FEV1) value ≥30% and ≤90% predicted.
  • Heterozygous for CF transmembrane conductance regulator gene (CFTR) F508del mutation and a minimal function mutation (F/MF genotypes).

PRINCIPAL INVESTIGATOR

  • Dr Siobhain Mulrennan

THIS CLINICAL TRIAL IS CURRENTLY CLOSED

Please register your interest for future clinical trials and we will contact you when a suitable trial becomes available.

Scroll to Top